The Metabolic Syndrome in Patients with First-episode Schizophrenia- prediction and prevention

2010 ◽  
Author(s):  
Lene Nyboe ◽  
Poul Videbech
Keyword(s):  
Metabolic Syndrome ◽  
First Episode ◽  
The Metabolic Syndrome ◽  
Prediction And Prevention ◽  
First Episode Schizophrenia

Combination of aripiprazole and olanzapine in first episode psychosis patient with metabolic syndrome: A case report

2017 ◽  
Vol 41 (S1) ◽  
pp. S755-S756
Author(s):  
I. Licanin ◽  
H. Senad
Keyword(s):  
Metabolic Syndrome ◽  
Complete Blood Count ◽  
Mental Health Center ◽  
First Episode ◽  
Metabolic Disturbances ◽  
The Metabolic Syndrome ◽  
Schizophrenia Spectrum ◽  
Patient Reported ◽  
Competing Interest ◽  
First Episode Schizophrenia

There are numerous factors that predispose patients with schizophrenia to develop metabolic syndrome and become overweight including: physical passivity, unhealthy diet and anti-psyhotic treatment. The prevalence of anti-psychotic-related metabolic disturbances has been reported to vary from 23% to 50% and clozapine and olanzapine had the most pronounced potential to cause metabolic syndrome. We present the case of 32-year-old male who has been diagnosed with first episode schizophrenia spectrum psychosis and has been treated for 3 months in the community mental health center. He was medication–compliant and was prescribed olanazapine 10 mg a day and had initial remission of symptoms. The reason behind referral to our department of psychiatry was development of metabolic syndrome. Immediately upon admission to our department basic panel blood tests (minerals, creatinin, glucose, tryglicerides and cholesterol) as well as complete blood count were done. Patient reported gaining weight of more than 5 kilograms since the initiation of the olanzapine treatment. Results of the performed metabolic tests in addition to abnormal BMI and slightly higher blood pressure have indicated presence of metabolic syndrome. In order to try to reverse metabolic syndrome aripiprazole was commenced adjunctive to olanzapine. During the first week the dosage of aripiprazole was 2.5 mg/day, second week 5 mg/day and then increased to 10 mg a day. Three weeks after adding aripiprazole to olanzapine lab values of holesterol, triglycerides, fasting glucose as well as BMI were significantly lowered and symptoms of the metabolic syndrome were mitigated. Treatment was well tolerated.Disclosure of interestThe authors have not supplied their declaration of competing interest.

Prevalence of the metabolic syndrome in patients at risk of psychosis

2016 ◽  
Vol 33 (S1) ◽  
pp. S92-S92
Author(s):  
J. Cordes ◽  
A. Bechdolf ◽  
S. Moebus
Keyword(s):  
Metabolic Syndrome ◽  
Genetic Factors ◽  
Fasting Blood Glucose ◽  
First Episode Psychosis ◽  
First Episode ◽  
Clinical High Risk ◽  
Prodromal Symptoms ◽  
The Metabolic Syndrome ◽  
Episode Psychosis ◽  
Patients At Risk

The metabolic syndrome (MetS) is one of the most frequent reasons for the higher mortality in patients with schizophrenia. It is difficult to separate between effects of medication or the disorder itself on the development of MetS. In the present study, patients at clinical high risk for first-episode psychosis (CHR) were examined and the prevalence of the MetS was assessed. One hundred and sixty-three unmedicated antipsychotic naïve CHR patients aged between 18 and 42 years and suffering from unmanifested prodromal symptoms were compared to 35,869 patients of the “German Metabolic and Cardiovascular Risk Study” (GEMCAS). We observed a slightly higher prevalence of single MetS criteria in CHR group compared to the GEMCAS sample, in particular: high blood pressure (35.0 vs. 28.0%), waist circumference (17.6 vs. 15.1%), and high fasting blood glucose (9.4 vs. 4.0%). We assume the higher risk for MetS in schizophrenia patients or CHR patients to derive from genetic factors.Disclosure of interestIn cooperation with Joachim Cordes, Andreas Bechdolf, Christina Engelke, Kahl KG, Chakrapani Balijepalli, Christian Lösch, Joachim Klosterkötter, Michael Wagner, Wolfgang Maier, Andreas Heinz, Walter de Millas, Wolfgang Gaebel, Frank Schneider, Martin Lambert, Georg Juckel, Thomas Wobrock, Michael Riedel, Susanne Moebus.

Metabolic syndrome or glucose challenge in first episode of psychosis?

2017 ◽  
Vol 41 (1) ◽  
pp. 42-46 ◽  
Author(s):  
C. Garcia-Rizo ◽  
E. Fernandez-Egea ◽  
C. Oliveira ◽  
A. Meseguer ◽  
B. Cabrera ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
Control Sample ◽  
Diagnostic Tools ◽  
First Episode ◽  
Unhealthy Lifestyle ◽  
Affective Psychosis ◽  
The Metabolic Syndrome ◽  
Glucose Challenge ◽  
New Strategies

AbstractPatients with schizophrenia exhibit a reduced life expectancy. Although unhealthy lifestyle or suicide risk plays a role, the main causes are diverse medical conditions such as cardiovascular diseases, type 2 diabetes mellitus and metabolic syndrome. Albeit pharmacological secondary side effects might also trigger previous conditions, studies in naïve patients reflect diverse anomalies at the onset. Patients with a first episode of psychosis, display a wide scope of metabolic abnormalities, ranging from normality till pathological values depending on the parameters studied. We attempted to evaluate the metabolic syndrome and glycemic homeostasis in a subset of antipsychotic-naïve patients with a first episode of non-affective psychosis. Patients (n = 84) showed a similar prevalence of metabolic syndrome compared with a matched control sample (n = 98) (6% vs 4%, P = 0.562), while glucose homeostasis values differed significantly (14% vs. 5%, P = 0.034). Our results suggest that metabolic syndrome is not a useful clinical condition to be evaluated in patients before pharmacological treatment. Abnormal glycemic homeostasis at the onset of the disease requires specific diagnostic tools and preventive measures in order to avoid future cardiovascular events. New strategies must be implemented in order to evaluate the cardiovascular risk and subsequent morbidity in patients at the onset of the disease.

Sign in / Sign up

Export Citation Format

Share Document